부산대학교 도서관

Bone alkaline phosphatase (BAP) is an enzyme which plays an important role in the bone formation and in mineralization. It reflects the metabolic status of osteoblasts. The objective of this study was to determine the usefulness of the BAP measurement in serum in osteoporosis patients. The study group included 97 patients with postmenopausal osteoporosis, validated by DEXA (group 1), treated with risedronate and a control group of 90 premenopausal women (group 2). For both groups, the BAP serum level is measured (by ELISA technique) at baseline and after 6 and 12 months. The analysis of the therapy efficiency in osteoporosis to the study group was performed using the DEXA method, after 12 months of treatment. BAP0/6/12 months(μg/L) - group 1: 13.98 ± 6.50/ 11.88 ± 4.89 / 11.20 ± 3.94; BAP0/6/12 months(μg/L) - group 2: 7.83 ± 2.28/ 7.89 ± 3.21/ 7.55 ±1.68. The BAP values were significantly elevated at the osteoporosis patients at the baseline determination. Subsequently, we have observed a significant negative correlation between the values of this bone formation marker and BMD (r= -0.350, p<0.03). For the patients with elevated BMD (undergoing treatment), the BAP values showed an accentuated decrease 6 months after the beginning of the therapy and continued to decrease until the following determination. The BAP determination is useful, as it reflects the changes at the level of bone remodeling due to the osteoporosis therapy. The significant decrease of BAP at 6 months shows the efficiency of the treatment. [ABSTRACT FROM AUTHOR]